Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Drug Discovery Today|July 22, 2014
Personalizing prostate cancer therapy: the way forwardJeremy P Cetnar, Tomasz M Beer
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 23, 2026
Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung CancerRaymond U Osarogiagbon, Jeremy P Cetnar, Raid Aljumaily
Plos One|February 6, 2013
Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinomaJonathan A Ewald, Tracy M Downs, Jeremy P Cetnar, et al.
Journal of the National Cancer Institute|May 5, 2025
Landscape assessment of patient-reported outcome item coverage of tyrosine kinase inhibitor-associated AEsEmily L Paton, Jeremy P Cetnar, Janet Freeman-Daily, et al.
Urology|February 19, 2008
Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancerJeremy P Cetnar, S Bruce Malkowicz, Steven C Palmer, et al.
Urologic Oncology|March 18, 2014
NLR is predictive of upstaging at the time of radical cystectomy for patients with urothelial carcinoma of the bladderAaron Potretzke, Luke Hillman, Kelvin Wong, et al.
Cancer|October 11, 2014
Antioxidant micronutrients and the risk of renal cell carcinoma in the Women's Health Initiative cohortWon Jin Ho, Michael S Simon, Vedat O Yildiz, et al.
Urology|January 22, 2013
Place of residence and primary treatment of prostate cancer: examining trends in rural and nonrural areas in WisconsinJeremy P Cetnar, John M Hampton, Amy A Williamson, et al.
Oncotarget|July 19, 2016
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancerJulie N Graff, Joshi J Alumkal, Charles G Drake, et al.
European Urology Oncology|December 28, 2023
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant ChemotherapyPetros Grivas, Vadim S Koshkin, Xiangying Chu, et al.
Pageof 2